Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | SHBG | P04278 | 3/20 | 0.74 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | G6PD | P11413 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.74 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.74 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154339 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL3115963 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL19750432 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL19253221 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL5173849 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL13302861 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL3115971 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL10060830 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| Androsterone SCHEMBL23031469 | 0.85 | G6PD (1.00) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| Androsterone SCHEMBL12811704 | 0.85 | G6PD (1.00) | GPBAR1LMNACYP3A4SHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080038316-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2008-02-14 | — | — | US | claimed |
| JP-3378245-B2 | — | — | 2003-02-17 | — | — | JP | claimed |
| US-6011023-A | Angiostatic steroids | ALCON LABORATORIES, INC. (US) | 2000-01-04 | — | — | US | claimed |
| US-5371078-A | Angiostatic steroids and methods and compositions for controlling ocular hypertension | ALCON LABORATORIES, INC. (US) | 1994-12-06 | — | — | US | claimed |
| EP-0614463-A1 | ANGIOSTATIC STEROIDS | ALCON LABORATORIES, INC. (US) | 1994-09-14 | — | — | EP | claimed |
| WO-1993010141-A2 | ANGIOSTATIC STEROIDS | ALCON LABORATORIES, INC. (US) | 1993-05-27 | — | — | WO | claimed |
| US-10744202-B2 | Sustained release eye drop formulations | RAMSCOR, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10668190-B2 | Multiphase gel | BVW HOLDING AG (CH) | 2020-06-02 | — | — | US | disclosed |
| EP-3186267-B1 | AMPHIPHILIC COMPOUNDS WITH NEUROPROTECTIVE PROPERTIES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-10-02 | — | — | EP | disclosed |
| US-20180289810-A1 | SUSTAINED RELEASE EYE DROP FORMULATIONS | RAMSCOR, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-10017535-B2 | Amphiphilic compounds with neuroprotective properties | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2018-07-10 | — | — | US | disclosed |
| US-9993558-B2 | Sustained release eye drop formulations | RAMSCOR, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9981041-B2 | Ophthalmic lubricating spray | SALZMAN IRA JASON (US) | 2018-05-29 | — | — | US | disclosed |
| US-20090136445-A1 | SUSTAINED RELEASE EYE DROP FORMULATIONS | RAMSCOR, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080234245-A1 | Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma | ALCON, INC. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080038316-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20050239760-A1 | Angiostatic agents and methods and compositions for controlling ocular hypertension | ALCON, INC. | 2005-10-27 | — | — | US | disclosed |
| EP-1236469-A2 | Angiostatic steroids | Alcon Laboratories, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1236471-A2 | Angiostatic steroids | Alcon Laboratories, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1236470-A2 | Angiostatic steroids | Alcon Laboratories, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239760-A1 | Angiostatic agents and methods and compositions for controlling ocular hypertension | VEGFA, SERPINA6, TIMP3 | GPBAR1 3489/4885LMNA 2083/4885CYP3A4 4879/4885 |
| US-20080234245-A1 | Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma | VEGFA, SERPINA6, SERPINE1 | GPBAR1 4017/4885LMNA 3304/4885CYP3A4 4854/4885 |
| US-10017535-B2 | Amphiphilic compounds with neuroprotective properties | GAP43, GRIN2A, GRIN3A | GPBAR1 287/4885LMNA 1572/4885CYP3A4 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.